TNFSF10 and cancer: Consistently, they demonstrated that GALNT14 knockdown decreased ligand-induced receptor clustering, with subsequent inhibition of the extrinsic apoptotic signaling, highlighting the potential use of GALNT14 as a predictive biomarker for Apo2L/TRAIL-based cancer therapy [37].